Prevail Therapeutics Inc.
https://www.prevailtherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Prevail Therapeutics Inc.
Sangamo’s Fabry Gene Therapy Can Rely On 25-Person Registration Trial After US FDA Meeting
With a PRIME designation also in hand for isaralgagene civaparvovec, Sangamo still needs to secure a partner before beginning its pivotal trial, which importantly will not have to include a head-to-head comparison with enzyme replacement therapies.
Sangamo Shoots Up As Regulatory Path Clears For Fabry Gene Therapy
The US group has had a tough year but the signs look more promising for isaralgagene civaparvovec as the FDA agrees on the design for a registrational trial for the gene therapy. Now Sangamo needs to secure a partner.
Allo CAR-T Is Still On The Shelf As Precision Moves On
Precision Biosciences is exiting the allogeneic CAR-T field after four years in early clinical trials, selling off its former lead asset for just $21m.
Deal Watch: Sangamo Inks Significant Option Deal With Prevail After Losing Tie-Ups With Novartis, Biogen
Plus deals involving Novartis/DTx, Neurogene/Neoleukin, Travere/Mirum, Sanofi/Scribe, Korro Bio/Frequency, MaxCyte/viTToria and more.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice